Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...
India has firmly established itself as the world's major producer of generic drugs. It is currently ranked third in ...
Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of ...
Alvotech's biosimilars aim to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes.
Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...
The European Medicines Agency (EMA) could table proposals next year to relax requirements around the need for comparative ...
Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster ...
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
The major pharmaceutical companies of the country reported a 10 per cent year-on-year (YoY) growth in the second quarter of ...
Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster ...
Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making ...
pharmaphorum interviews Dr Conrad Savoy on the challenges involved with getting biosimilars and biobetters to market, and also the opportunities they present. Biosimilars and biobetters present a ...